Length of hospital stay and associated costs for olanzapine vs. haloperidol in the treatment of schizophrenia relapse in Germany

European Journal of Health Economics

Volumn 4, Issue 2, 2003, Pages 85-89

  Spannheimer, A ^a,d   Reitberger, U ^a   Clouth, J ^b   Lothgren, M ^c  

^a Kendle International Inc   (Germany)

^b LILLY DEUTSCHLAND GMBH   (Germany)

^c European Health Outcomes Research   (United Kingdom)

^d Kendle GmbH   (Germany)

Author keywords

Cost analysis; Haloperidol; Hospital stay; Olanzapine; Schizophrenia

Indexed keywords

HALOPERIDOL; OLANZAPINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG COST; FEMALE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MENTAL HOSPITAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SYMPTOMATOLOGY;

EID: 0037930216     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-002-0161-2     Document Type: Article

References (8)

1. Bhana N, Foster RH, Olney R, Plosker GL (2001) Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 61:111-161
2. Deckert C, Höffler J, Kortmann J, Linden M, Roth G-D, Struck M, Clouth J, Czekalla J, Spannheimer A, Wieseler B, Schlereth T (2001) Kostenanalyse der Schizophrenie-Behandlung in Deutschland Vergleich von Olanzapin, Risperidon und Haloperidol mit Hilfe eines klinischen Entscheidungsmodells. Gesundh Okon Qual Manag 6:161-166
3. Foster RH, Goa KL (1999) Olanzapine a pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics 15:611-640
4. Hamilton SH, Revicki DA, Edgell ET, Genduso LA, Tollefson G (1999) Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Pharmacoeconomics 15:469-480
5. Le Pen C, Lilliu H, Allicar MP, Olivier V, Gregor KJ (1999) Economic comparison of olanzapine versus haloperidol in the treatment of schizophrenia in France (French). Encephale 25:281-286
6. Rössler W, Salize HJ (1996) Die psychiatrische Versorgung chronisch psychisch Kranker: Daten, Fakten, Analysen. Nomos: Baden-Baden
7. Spannheimer A, Clouth J (1999) Pharmacoeconomic evaluation of the treatment of schizophrenia in Germany: a comparison of olanzapine and haloperidol. Presented at the XI World Congress of Psychiatry 6-11 Aug, Hamburg
8. Verband der privaten Krankenversicherung (1998) Krankenhausstatistik